GET DAILY SIGNALSDisc Medicine (IRON) Narrows Q3 Loss to $1.53 Per Share as Bitopertin Advances
Key Takeaways
- Disc Medicine reported a net loss of $59.5 million, or $1.53 per share, for the third quarter of 2026, beating consensus estimates.
- Revenue remained $0, consistent with the company's pre-commercial stage as its lead drug candidate, bitopertin, advances toward regulatory review.
- Positive Phase 3 APOLLO results for bitopertin in EPP were the quarter's defining event, with an NDA (New Drug Application) resubmission planned by the end of 2026.
- Cash, cash equivalents, and marketable securities totaled $682.8 million, and an October 2026 offering added roughly $485.9 million in net proceeds, extending the runway into 2030.
- Research and development (R&D) expenses declined year over year to $44.1 million, helped by non-recurring prior-year costs.
- Investors can find additional context through the company's Major News, Today's Price Move, Price Targets, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven strategies are scanning the market for opportunities.
Why These Results Matter
Disc Medicine remains a clinical-stage biopharmaceutical company focused on serious hematologic diseases, with no approved products and therefore no product revenue. Quarterly results for these companies tend to center on cash management, spending control, and pipeline updates rather than sales figures. The third quarter of 2026 stood out because it came right after the first pivotal Phase 3 readout from the APOLLO trial of bitopertin in erythropoietic protoporphyria, a rare condition marked by severe light sensitivity. Positive data lifted the stock and shifted attention toward the regulatory path ahead.
The Quarter in Detail
For the period ended September 30, 2026, Disc Medicine posted a net loss of $59.5 million, or $1.53 per share, compared with $62.3 million, or $1.77 per share, a year earlier. The per-share loss came in better than the consensus range of roughly $1.71 to $1.76. Revenue stayed at zero, as expected in the pre-commercial phase.
Research and development spending fell to $44.1 million from $50.3 million, mainly because a $10.0 million milestone payment and certain manufacturing costs from the prior year did not repeat. Selling, general, and administrative expenses rose to $20.1 million from $17.4 million due to increased headcount. Cash, cash equivalents, and marketable securities reached $682.8 million at quarter end. An October 2026 public offering brought in about $485.9 million in net proceeds, pushing the projected cash runway into 2030. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Sentiment
Disc Medicine shares rose more than +70% in mid-October following the positive APOLLO Phase 3 results. By the time of the November 5 earnings release, focus had moved from the quarterly loss to the timeline for regulatory approval and commercialization. The narrower loss supported views of disciplined spending, and management’s plan to resubmit the NDA by the end of 2026 kept the tone constructive. Analyst coverage stays bullish overall, with a strong buy rating and average price targets well above recent levels.
What Comes Next
The key near-term catalyst remains the planned NDA resubmission for bitopertin by the end of 2026, with an FDA decision expected around mid-2027. I’m watching closely for acceptance confirmation, any priority review designation, and updates on commercial infrastructure build-out.
Additional pipeline readouts will also matter. Disc Medicine plans further data from the DISC-0974 program in myelofibrosis-related anemia and from DISC-3405 in polycythemia vera and sickle cell disease. These expand the opportunity set but will add to development costs.
Cash burn and the balance sheet will stay in focus. With the runway now extending into 2030, the company has room to operate, yet rising SG&A and personnel expenses tied to commercial readiness could widen losses in upcoming quarters. Monitoring spending alongside regulatory and clinical milestones remains essential.
AI Tools in My Research Process
When evaluating clinical-stage names like this, I often run quick screens to place the stock in broader context. Tickeron’s AI Screener lets me filter by industry, market cap, and technical signals in one place, which helps surface comparable opportunities without spending hours on manual checks. It has become a regular part of how I organize ideas before digging deeper into filings or trial data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRON in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026
The 10-day moving average for IRON crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on IRON as a result. In 79 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for IRON just turned positive on October 19, 2026. Looking at past instances where IRON's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
IRON moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRON advanced for three days, in 241 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for IRON moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 31 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 63 cases where IRON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
IRON broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IRON entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.677) is normal, around the industry mean (2.904). P/E Ratio (-11.907) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. IRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 46 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a blank check company, which was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
Advertisement